Eagle Capital Management 13F: Adds $18M to ELV Stake

Eagle Capital Management has increased its stake in Elevance Health, Inc. (NYSE:ELV) by 44,559 shares, according to its latest 13F filing with the SEC. This move brings Eagle Capital's total holdings to 1,548,610 shares, valued at approximately $618.2 million. The filing reflects positions as of the end of the reporting period and may not represent current holdings.

What Changed in Eagle Capital Management's Elevance Health Position

Eagle Capital Management boosted its position in Elevance Health by 44,559 shares, raising its total to 1,548,610 shares. This represents a 2.96% increase from its previous holding of 1,504,051 shares, with the new stake valued at $618.2 million.

Other Institutional Activity in Elevance Health

Several other institutional investors have also adjusted their positions in Elevance Health. BlackRock, Inc. reduced its holdings by 515,523 shares, ending with 19,887,111 shares valued at about $5.82 billion. Vanguard Capital Management LLC added 14,345,459 shares, bringing its total to the same number of shares worth approximately $4.20 billion. State Street Corp trimmed its position by 52,770 shares, holding 10,288,696 shares valued at $3.01 billion. Meanwhile, Sanders Capital, LLC increased its stake by 143,438 shares, resulting in 5,894,303 shares valued at $1.73 billion.

Elevance Health, Inc. Stock Down 2.9%

Shares of Elevance Health (NYSE:ELV) are trading around $399.18. The company has a market cap of $87.7 billion, with a P/E ratio of 17.1 and a forward P/E of 13.8. Its beta is 0.682, indicating lower volatility compared to the broader market. The stock's 52-week range is between $273.71 and $426.98, with a 50-day moving average of $365.57 and a 200-day moving average of $339.13.

Recent Earnings

Elevance Health reported revenue of $200.4 billion, with a growth rate of 2.6%. The company achieved a net margin of 2.6% and a return on equity of 12.1%. Earnings per share (EPS) stood at $23.59. The next earnings report is expected on April 22, 2026.

Dividend

Elevance Health offers an annual dividend rate of $6.88, yielding 1.72%. The dividend payout ratio is 29.03%, reflecting a sustainable payout relative to earnings.

Insider Buying and Selling at Elevance Health, Inc.

Recent insider activity at Elevance Health includes several transactions. On May 19, 2026, Ronald Penczek, the Chief Accounting Officer & Controller, sold 1,531 shares at an average price of $403.13. Earlier, on May 13, 2026, Ramiro Peru and Steven Collis each purchased 563 shares.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for Elevance Health. On June 8, 2026, Mizuho and JP Morgan both maintained their 'buy' ratings with targets of $465 and $476, respectively. Earlier, on June 4, 2026, B of A Securities maintained a 'buy' rating with a $460 target, while Morgan Stanley held a 'hold' rating with a $404 target. The consensus recommendation remains a 'buy' with an average target price of $415.81 based on 21 analyst opinions.

About Elevance Health

Elevance Health, Inc., headquartered in Indianapolis, Indiana, operates as a health benefits company in the U.S. It provides a range of health plans and services through its segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company serves various members, including those in Medicare and Medicaid. It also operates pharmacy services and offers specialty care management.

Bottom Line

Eagle Capital Management's increase in its Elevance Health stake signals continued interest in the healthcare sector. Investors track such institutional moves to gauge market sentiment, though 13F filings are backward-looking and may not reflect current positions. Elevance Health's performance and analyst outlooks suggest it remains an important player in the healthcare industry.